Zohar Sachs, MD, PhD

Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation

Zohar Sachs

Contact Info

sachs038@umn.edu

Office Phone 612-626-7055

Mailing Address:
Division of Hematology, Oncology and Transplantation
420 Delaware Street SE
MMC 480
Minneapolis, MN 55455

Administrative Assistant Name
Tracy Daye-Groves

Administrative Phone
612-624-5944

Administrative Email
tmgroves@umn.edu

Administrative Fax Number
612-625-6919

Medical School, Tufts University School of Medicine, Boston, MA

Residency, Caritas St. Elizabeth's Medical Center, Brighton, MA

Fellowship, University of Minnesota, Minneapolis, MN

Summary

Dr. Zohar Sachs received her undergraduate degree, a BS in Chemical Engineering, from the Massachusetts Institute of Technology (Cambridge). She then attended the Tufts Medical School Medical Scientist Training Program (Boston), receiving an MD/PhD. Dr. Sachs completed her residency in Internal Medicine at Caritas St. Elizabeth’s Medical Center (Boston). Dr. Sachs conducted her fellowship in Hematology, Oncology and Transplantation at the University of Minnesota. In 2012 she became a member of the faculty.

Dr. Sachs leads a basic and translational research lab focused on identifying the molecular mechanisms of self-renewal in acute myelogenous leukemia.

Research

Research Summary/Interests

Acute myeloid leukemia stem calls
My lab’s goal is to identify molecular mechanisms of leukemia stem cell self-renewal in primary murine and human acute myeloid leukemia (AML). Self-renewal is a feature of leukemia stem cells that allow them to recapitulate leukemia and cause relapse. Since AML cells are highly heterogenous, we specialize in the application of single-cell, high throughput technologies (including mass cytometry/CyTOF and single-cell RNA sequencing) to address these research questions.

My earlier work demonstrated that the activated NRAS oncogene mediates self-renewal in AML and that individual leukemia cells vary significantly in their functional status and ability to self-renew (Sachs et al. Blood 2014). Recently, we defined the gene expression profile of AML self-renewal at the single-cell level and used this data to identify a functionally unique subset of leukemia cells with leukemia-repopulating potential. We are using these approaches to identify effective therapeutic targets for this deadly disease.

Publications

  • Baughn LB*, Sachs Z*, Noble-Orcutt KE, Mitra A, Van Ness BG, and Linden MA.“Phenotypic and functional characterization of a bortezomib resistant multiple myeloma cell line by flow and mass cytometry.”
  • Leukemia and Lymphoma. 2016 Dec 16:1
    *co-first authors
  • Maus R, Jakub JW, Nevala W, Christensen T, Noble-Orcutt K, Sachs Z, Hieken T, Markovic SN. 2017. “Human melanoma-derived extracellular vesicles regulate dendritic cell maturation.” Frontiers in Immunology March 29;8:358.
  • Baughn LB*, Sachs Z*, Noble-Orcutt KE, Mitra A, Van Ness BG, and Linden MA. 2017.“Phenotypic and functional characterization of a bortezomib resistant multiple myeloma cell line by flow and mass cytometry.” Leukemia and Lymphoma 58(8):1931-1940. *co-first authors
  • Csizmar CM, Kim DH, Sachs, Z.“The Role of the Proteasome in AML.”
    Blood Cancer Journal. 2016 Dec 2;6(12)e503. doi: 10.1038/bcj.2016.112.
  • Sachs Z, Been RA, DeCoursin KJ, Nguyen HT, Mohd Hassan NA, Noble-Orcutt KE, Eckfeldt CE, Pomeroy EJ, Diaz-Flores E, Geurts JL, Diers MD, Hasz DE, Morgan KJ, MacMillan ML, Shannon KM, Largaespada DA, Wiesner SM. 2016. “Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.” Haematologica. Oct;101(10):1190-1199.
  • Yun YS, Kim KH, Tschida B, Sachs Z, Noble-Orcutt KE, Moriarity B, Ai T, Ding R, Williams J, Chen L, Largaespada DA, Kim D. 2016. “mTORC1 Regulates Immunoproteasome Assembly for Protein Stress Response and Cell Survival.” Molecular Cell. Feb 18;61(4):625-39.
  • Moench L, Sachs Z, Aasen G, Dolan M, Dayton V, Courville EL. 2016.“Double- and Triple-Hit Lymphomas Can Present with Immature Features, including TdT Expression, and Create Diagnostic Challenges.” Leukemia and Lymphoma. Feb 18:1-10.
  • Trottier BJ, Sachs Z, DeFor TE, Shune L, Dolan M, Weisdorf DJ, Ustun C, Warlick ED. 2016. “Novel Disease Burden Assessment Predicts Allogeneic Transplantation Outcomes in Myelodysplastic Syndrome.” Bone Marrow Transplant. Feb;51(2):199-204.
  • Courville EL, Sachs Z, Linden MA. Plasma Cell Neoplasms: A morphologic, cytogenetic, and Immunophenotypic approach. Linden MAMcKenna RW, Editors. New York, NY: Springer; 2015. Standardized synoptic reports for plasma cell neoplasms: integration of laboratory and clinical data.
  • Kempema AM, Widen JC, Hexum JK, Andrews TE, Wang D, Rathe SK, Meece FA, Noble KE, Sachs Z, Largaespada DA, Harki DA. Synthesis and antileukemic activities of C1-C10-modified parthenolide analogues. Bioorg Med Chem. 2015 Aug 1;23(15):4737-45. doi: 10.1016/j.bmc.2015.05.037. Epub 2015 May 30. PMID: 26088334
  • Ustun C, Trottier BJ, Sachs Z, DeFor TE, Shune L, Courville E, Holtan SG, Dolan M, Weisdorf DJ, Warlick ED. Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2015 Jan 22. pii: S1083-8791(15)00051-8. doi: 10.1016/j.bbmt.2015.01.017. [Epub ahead of print]. PMID: 25620751
  • Sachs Z, LaRue RS, Nguyen HT, Sachs K, Noble KE, Mohd Hassan NA, Diaz-Flores E, Rathe SK, Sarver AL, Bendall SC, Ha NA, Diers MD, Nolan GP, Shannon KM, Largaespada DA. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia. Blood. 2014 Nov 20;124(22):3274-83. doi: 10.1182/blood-2013-08-521708. Epub 2014 Oct 14. PMID: 25316678
  • Fall DJ, Stessman H, Patel SS, Sachs Z, Van Ness BG, Baughn LB, Linden MA. Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma. J Cancer. 2014 Sep 21;5(9):720-7. doi: 10.7150/jca.9864. eCollection 2014. Review. PMID: 25368671
  • Liegel J, Courville E, Sachs Z, Ustun C. Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect. Haematologica. 2014 Nov;99(11):e222-4. doi: 10.3324/haematol.2014.109975. Epub 2014 Jul 11. PMID: 25015937
  • Lunde L, Chuang C, Linden M, Williams S, Sachs Z, Cayci Zuzan, Young J, Ustun C. Lethal small bowel necrosis due to aspergillosis during acute promyelocitic leukemia induction. Am J Hematology 2013;88(4):329-332. PMID: 22791390
  • Linden MA, Bachanova V, Sachs Z, Young JA, Singleton TP, Ustun C. Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumab. Leuk Lymphoma 2013 Jan;54(1):174-6.
  • Sachs Z, Sharpless N, DePinho R, Rosenberg, N. p16Ink4a induces apoptosis during Ab-MLV transformation of pre-B cells. J Virol. 2004;78(7):3304-11.
  • Mostecki J, Halgren A, Radfar A, Sachs Z, Ravitz J, Thome KC, Rosenberg N. Loss of heterozygosity at the Ink4a/Arf locus facilitates Abelson virus transformation of pre-B cells. J Virol 2000;74(20):9479-87.
  • Berretta S, Sachs Z, Graybiel AM. Cortically driven Fos in the striatum is amplified by local dopamine D2-class receptor blockade. Eur J Neurosci. 1999;11:4309-19.

Clinical

Specialties

  • Cancer
  • Hematology/Oncology

Clinics

Masonic Cancer Center

Board Certifications

  • Internal Medicine
  • Hematology

Clinical Interests

AML; Myeloid malignancies; Leukemia; Bone marrow diseases; Lymphoma; Myelodysplastic syndrome